NCT04883710Not yet recruiting
The World Federation of Hemophilia Gene Therapy Registry
Source: ClinicalTrials.gov · Last updated 12 May 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of the WFH GTR is to provide a database in which long-term data on PWH who receive gene therapy from around the world, will be collected and housed.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 20 Feb 2020
- Start date
- 1 Jan 2022
- Primary completion date
- 1 Jan 2050
- Lead sponsor
- World Federation of Hemophilia
- Diseases
- Haemophilia
- NCT number
- NCT04883710
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Jan 2022 to the primary completion date, 1 Jan 2050
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- People with hemophilia who have received a gene therapy product
Age in the registry: 0 years to 100 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.